{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058618","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.956673+00:00","generated_at":"2026-06-02T02:31:57.826589+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AVITA Medical Q1 revenue $11.1M (+5.8%), net loss $18.7M; lowers 2024 revenue guidance to lower end","bullets":["Commercial revenue $11.1M, up 5.8% YoY; gross margin 86.4%.","Net loss $18.7M ($0.73/share) vs $9.2M loss ($0.37) in Q1 2023; operating expenses $26.8M.","Full-year 2024 commercial revenue expected at lower end of $78.5-84.5M range, implying ~57% growth.","Launched PermeaDerm biosynthetic wound matrix in US on March 23, 2024.","RECELL GO FDA decision by May 30, 2024; cashflow breakeven targeted no later than Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058618","json":"https://secwatch.observer/filing/0000950170-24-058618.json","markdown":"https://secwatch.observer/filing/0000950170-24-058618.md","text":"https://secwatch.observer/filing/0000950170-24-058618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024058618/0000950170-24-058618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024058618/rcel-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:31:57.826589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e47fa4788e030c428da101883d089a073737ca6","claim":"AVITA Medical, Inc. updated its first quarter ended March 31, 2024 guidance (lowered).","evidence_excerpt":"On May 13, 2024, AVITA Medical, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024058618/0000950170-24-058618-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}